Related references
Note: Only part of the references are listed.Lynch syndrome-related non-endometrioid endometrial cancer: analysis of outcomes
Giorgio Bogani et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer
Casper Reijnen et al.
GYNECOLOGIC ONCOLOGY (2019)
Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer
A. Oaknin et al.
GYNECOLOGIC ONCOLOGY (2019)
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
Stephanie M. de Boer et al.
LANCET ONCOLOGY (2019)
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
Daniela Matei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
LBA63Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy
C L Creutzberg et al.
ANNALS OF ONCOLOGY (2019)
Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer
Chelain R. Goodman et al.
GYNECOLOGIC ONCOLOGY (2019)
Adjuvant therapy in stage III endometrial cancer confined to the pelvis
Reem Albeesh et al.
GYNECOLOGIC ONCOLOGY (2019)
Immune mechanisms mediating abscopal effects in radioimmunotherapy
Maria E. Rodriguez-Ruiz et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Does MMR status in endometrial cancer influence response to adjuvant therapy?
Soyoun Rachel Kim et al.
GYNECOLOGIC ONCOLOGY (2018)
Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers
Claire Vanpouille-Box et al.
CLINICAL CANCER RESEARCH (2018)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Opportunities for immunotherapy in microsatellite instable colorectal cancer
Harm Westdorp et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas
Ayumi Shikama et al.
GYNECOLOGIC ONCOLOGY (2016)
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
D. Scott McMeekin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Current clinical trials testing the combination of immunotherapy with radiotherapy
Josephine Kang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Microsatellite Instability Detection by Next Generation Sequencing
Stephen J. Salipante et al.
CLINICAL CHEMISTRY (2014)
Mismatch repair status and clinical outcome in endometrial cancer: A systematic review and meta-analysis
Ivan Diaz-Padilla et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
Randomized phase Ill noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study
D. Miller et al.
GYNECOLOGIC ONCOLOGY (2012)
Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer
Floor J. Backes et al.
GYNECOLOGIC ONCOLOGY (2009)
The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer
Angeles Alvarez Secord et al.
GYNECOLOGIC ONCOLOGY (2007)
Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type
Israel Zighelboim et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer
Kathryn Greven et al.
GYNECOLOGIC ONCOLOGY (2006)
Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements
JG Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A gynecologic oncology group study
GF Fleming et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-κB activation by camptothecin and X-ray
Y Habraken et al.
ONCOGENE (2003)
The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase
A Franchitto et al.
ONCOGENE (2003)
Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: A phase II study
PJ Hoskins et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Stage IVB endometrial carcinoma: The role of cytoreductive surgery and determinants of survival
RE Bristow et al.
GYNECOLOGIC ONCOLOGY (2000)
Share Paper
